Olanzapine: Another psychotropic?

Davis, Mellar P.; Dickerson, E. Duke

doi:10.1177/104990910101800212

Cited by 16 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These therapeutic advances notwithstanding, some patients remain plagued with nausea, which is resistant to all current forms of pharmacotherapy. 13 Despite the theoretic appeal of olanzapine as an antiemetic, and claims regarding its potential efficacy, 14,15 little data have been published to delineate its role in the treatment of specific patient types. A single case report 11 indicated success in a depressed, agitated woman who suffered from chemotherapeutic-induced nausea (with a strong anticipatory component), which had been recalcitrant to previous treatment with ondansetron, dexamethasone, prochlorperazine, metoclopramide, and cisapride.…”

Section: Discussionmentioning

confidence: 99%

Olanzapine for Intractable Nausea in Palliative Care Patients

Jackson

Tavernier²

2003

Journal of Palliative Medicine

View full text Add to dashboard Cite

Nausea is a common problem among palliative care patients, which is often undertreated. Olanzapine, an atypical antipsychotic, possesses a unique neurotransmitter binding profile that is similar to methotrimeprazine, an anti-emetic widely used in Europe for recalcitrant nausea. We report a case series of six patients who suffered nausea which was resistant to initial treatment with traditional antiemetics; each patient exhibited marked improvement when treated with olanzapine.

show abstract

Section: Discussionmentioning

confidence: 99%

Olanzapine for Intractable Nausea in Palliative Care Patients

Jackson

Tavernier²

2003

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

“…2005). Olanzapine has been used as adjunctive therapy in depressive disorders in general (Goodnick & Barrios 2001) and has also been used for managing psychotic or mood symptoms in advanced cancer patients since it also has favourable action in nausea (Davis & Dickerson 2001; Davis et al . 2002).…”

Section: Discussionmentioning

confidence: 99%

Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition

Douzenis¹,

Michopoulos²,

Economopoulos³

et al. 2007

Eur J Cancer Care

View full text Add to dashboard Cite

show abstract

“…Psychosocial interventions also are recommended in addition to medication and psychotherapy. Other psychotropic medications mentioned in the recent literature that potentially improve the quality of life for patients near the end of their lives who suffer from depression disorders, psychoses, or pain include methylphenidate [31,32] and modafinil [33] to relieve fatigue and depression and provide more energy for some patients, mirtazepine [34,35] and venlafaxine [36] to address depressive and pain-related problems, and olanzapine [37] and risperidone [38] to address delirium and psychoses-related behaviors.…”

Section: Depression Recognition and Management At The End Of Lifementioning

confidence: 98%

The psychiatric management of end-of-life pain and associated psychiatric comorbidity

Cole

2003

Current Science Inc

View full text Add to dashboard Cite

Involvement by psychiatrists in the care of patients who are terminally ill has been limited historically; however, psychiatrists increasingly are participating in the care of these people who are facing the most challenging times of their lives. Pain management is considered to be an area of subspecialization for psychiatrists beyond their traditional role of being psychopharmacologists and psychotherapists. Biologically focused psychiatrists are able to address neuropsychiatric disorders, including pain and depression in the medically ill, and actively improve the quality of life for dying patients and their family members. This article provides a review of the recent literature that has addressed the involvement of psychiatrists in end-of-life care. Beginning with an example of the scientific aspects of cancer-related treatment from a patient's perspective, and into the major treatment considerations, this article addresses pain, its recognition, and management challenges when the end of life approaches. The prompt recognition of frequently overlooked and underestimated concomitant depressions, delirium, dementia, and other mental disorders is important for mental health specialists. The importance of psychiatric care for patients who are terminally ill and the role of psychiatrists in the phase of care also are discussed.

show abstract

Olanzapine: Another psychotropic?

Cited by 16 publications

References 29 publications

Olanzapine for Intractable Nausea in Palliative Care Patients

Olanzapine for Intractable Nausea in Palliative Care Patients

Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition

The psychiatric management of end-of-life pain and associated psychiatric comorbidity

Contact Info

Product

Resources

About